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MicroRNA-16, Programmed
Cell Death Protein-4 (PDCD-4)
and Polycystic Ovarian
Syndrome
Sir,
Polycystic ovarian syndrome (PCOS) is a prevalent disease in
7-9% of the women of reproductive age.1 The severity of PCOS
can be determined by Rotterdam criteria, depending upon the
spectrum  of  characteristics  present,  including  hyperandro-
genism (H), and/or lack of ovulation (O), and/or ovarian cysts
(OC). These include category-1: H+O, category-2: O+OC, cate-
gory-3: H+OC, and category-4: all 3 characteristics present. Its
reproductive disturbances manifest as menstrual irregularities,
lack of ovulation, impaired follicular maturation, hyperandro-
genism,  which  eventually  funnel  to  infertility.  Its  metabolic
disturbances, present in almost half of PCOS patients,2 include
high blood pressure, insulin resistance, obesity and abnormal
lipid profile.1
Micro-RNAs have single strands and small segments of non--
coding RNA (18-25 nucleotides), which break down RNA and
prevent translation by binding to 3’-UTR at post-transcriptional
level, thus are important players in cell growth and death.1,3
Studies  focusing  on  altered  serum  miRNA  levels  in  PCOS,
suggest its use as a prognostic and diagnostic marker for PCOS.2
Figure 1: Diagrammatic representation of effect of MiRNA-16 and PDCD-4
on cell cycle.4
The association between miR-16 and programmed cell death
protein-4 (PDCD-4) and their contributory roles in the progres-
sion of PCOS is still under analytic study. PDCD-4, present on
chromosome 10q24, increases in PCOS and induces apoptosis
by down regulating RNA helicase activity during translation.
MiR-16, on chromosome 13q14, is low in PCOS. Fu et al. stated
that the level of miR-16 in the ovarian cortical cells and blood
was decreased in PCOS, while ovarian cortex’s PDCD-4 level
was increased.2 Contrarily, increased miR-16 in PCOS women’
granulosa cells promoted cellular proliferation and decreased
cell death, where a greater number of cells were in the S phase
and  few  in  GO-G1  phase,  while  increased  PDCD-4  and
decreased  miR-16  expression  reversed  these  effects.  High
testosterone levels in PCOS alter folliculogenesis by decreasing
miR-16 and increasing PDCD-4, resulting in more cell death and
decreased cellular proliferation.1 Thus, it can be concluded that
the impaired follicular growth and granulosa cell death in PCOS
can be improved by increasing miR-16 expression which has an
effect on PDCD-4 at the molecular level.1
MiRNA-16 levels can then serve as a confirmatory diagnostic
test for PCOS. Thus, a sensitive and specific diagnosis can be
carried  out  which  is  minimally  invasive,  less  expensive  and
comfortable for the patients, unlike transvaginal ultrasonog-
raphy.2
It shows isolated effects of MiRNA-16 and PDCD-4 on different
stages  of  the  cell  cycle.  Different  levels  of  miRNA-16  and
PDCD-4 change the balance of cells, particularly in the GO, G1
and S phase. High levels of PDCD-4 result in a positive impact
and an increase in the number of cells in the G0 and G1 phase,
while cause an opposite effect on the cells in S phase, i.e. a
decrease in their number. On the other hand, increased serum
levels of MiRNA-16 have opposite effects on the cells in the 3
phases. These findings agree with the findings of the cellular
proliferative and anti-apoptotic effect of MiRNA-16, as fewer
cells will be in the resting stage and more will be in the DNA
replicative stage, leading to the mitotically growing stage.
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